Evvy has secured $14.0 million in new funding to advance its mission in women's healthcare. The company specializes in unlocking precision women’s healthcare through novel female biomarkers, beginning with the vaginal microbiome.
Evvy's platform offers the first at-home vaginal microbiome test utilizing metagenomic sequencing to provide insights into vaginal health. This service combines state-of-the-art testing with precision clinical care and 1:1 coaching. The company aims to build real-world datasets to transform understanding of complex female health conditions. This funding round was backed by investors including General Catalyst, Left Lane Capital, and LabCorp.
The newly raised capital will be deployed to accelerate Evvy's growth initiatives and expand its research and development efforts. This includes scaling its innovative care delivery model and further developing its platform to enhance early and precise risk detection, condition definition, and personalized treatment in women's health. The company's team includes leading OB/GYNs and vaginal microbiome researchers from institutions such as UCSF, Stanford, and Harvard.
Evvy is one of the fastest-growing women’s health companies in the US, focused on delivering high-quality care while scaling novel R&D. The company envisions a future where female health is thoroughly understood, enabling more specific and nuanced approaches to care. This investment is expected to support Evvy's continued expansion and its pioneering efforts to redefine women's health.
.png&w=3840&q=75)
